Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?
- 28 March 2007
- journal article
- Published by Springer Science and Business Media LLC in Clinical & Experimental Metastasis
- Vol. 24 (2), 79-86
- https://doi.org/10.1007/s10585-007-9055-0
Abstract
Epidermal growth factor receptor (EGFR) signalling contributes to malignant transformation and survival. We studied molecular predictors of benefit from EGFR-modulating therapies in patients with cancer of unknown primary (CUP). Tumours from paraffin-embedded biopsies of 50 patients with CUP were stained for EGFR protein by immunohistochemistry. Polymerase chain reaction amplification, single-strand conformational polymorphism and direct sequencing were used to study EGFR intron 1 cytosine-adenosine (CA) repeat length as well as exon 18, 19, 21 activating mutations and amplification. Thirty-seven tumours (74%) expressed EGFR protein but only six (12%) strongly. Regarding intron 1 CA repeat length, we detected five alleles with CA repeat numbers 16–20, allele 16 being the most common (39%). All samples were heterozygous, the commonest genotype consisting of 16/18 dinucleotides (78%). Five samples had three intron 1 alleles and were associated with EGFR overexpression in 40% of cases. There was no evidence of EGFR exon 18, 19, 21 amplification. Two mutations were detected: Exon 21 2508 C > T, a silent nucleotide polymorphism (R836R) and a G > A substitution in sequences flanking exon 19 (IVS19 + 24G > A) resulting in aberrant mRNA splicing. Neither EGFR protein expression nor CA repeat length were prognostic factors for survival. Our data depict absence of molecular predictors of benefit from EGFR modulation in patients with CUP. Study of its molecular pathophysiology and targeting other molecular pathways may be warranted instead.Keywords
This publication has 26 references indexed in Scilit:
- Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeThe New England Journal of Medicine, 2005
- Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative‐PCR analysis of non‐homogeneous gene amplification and DNA sequence alterationsNeuropathology and Applied Neurobiology, 2005
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2005
- Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patientsAnnals of Oncology, 2005
- Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255Cancer Research, 2004
- Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancerInternational Journal of Cancer, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaSeminars in Oncology, 2002
- Addiction to Oncogenes--the Achilles Heal of CancerScience, 2002